328 related articles for article (PubMed ID: 1751811)
1. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Pedretti G; Calzetti C; Missale G; Fiaccadori F
Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
Miglio F; Valpiani D; Rossellini SR; Ferrieri A
Curr Med Res Opin; 1997; 13(10):593-601. PubMed ID: 9327194
[TBL] [Abstract][Full Text] [Related]
3. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
Mas A; Rodés J; Sunyer L; Rodrigo L; Planas R; Vargas V; Castells L; Rodríguez-Martínez D; Fernández-Rodríguez C; Coll I; Pardo A;
J Hepatol; 2003 Jan; 38(1):51-8. PubMed ID: 12480560
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.
Conn HO; Leevy CM; Vlahcevic ZR; Rodgers JB; Maddrey WC; Seeff L; Levy LL
Gastroenterology; 1977 Apr; 72(4 Pt 1):573-83. PubMed ID: 14049
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial.
Uribe M; Farca A; Márquez MA; Garcĭa-Ramos G; Guevara L
Gastroenterology; 1979 Jun; 76(6):1347-51. PubMed ID: 374177
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.
Williams R; James OF; Warnes TW; Morgan MY
Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):203-8. PubMed ID: 10741936
[TBL] [Abstract][Full Text] [Related]
8. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin in the treatment of chronic hepatic encephalopathy.
Puxeddu A; Quartini M; Massimetti A; Ferrieri A
Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
[TBL] [Abstract][Full Text] [Related]
15. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.
Strauss E; Tramote R; Silva EP; Caly WR; Honain NZ; Maffei RA; de Sá MF
Hepatogastroenterology; 1992 Dec; 39(6):542-5. PubMed ID: 1483668
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
18. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial.
Atterbury CE; Maddrey WC; Conn HO
Am J Dig Dis; 1978 May; 23(5):398-406. PubMed ID: 354373
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin for the treatment of hepatic encephalopathy.
de Melo RT; Charneski L; Hilas O
Am J Health Syst Pharm; 2008 May; 65(9):818-22. PubMed ID: 18436728
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]